Massive growth is being forecast for the pharmaceutical and biotechnology markets of Middle Eastern states, driven by moves to liberalise national economies, the introduction of mass health insurance and the determination of the region’s governments to become self-sufficient in pharmaceuticals production.”
Major Pharmaceutical Markets of the Middle East (2nd Edition) is a comprehensive report providing extensive coverage of one of the strongest emerging markets. Through quality analysis and forecasts, this unique report will allow you to identify market trends and growth potential opportunities.
This best-selling report provides the necessary background information for a firm to operate in the region.
Chapter summaries:
Chapter 1: covers the main characteristics of the Middle Eastern market through a Political, Economic, Social and Technological (PEST) analysis, plus insight into the tax environment and Free-Trade Agreements in place or being negotiated.
Chapter 2: reports on the Intellectual Property Rights environment of each of the countries covered.
Chapter 3: provides a overview of the regional pharmaceutical market, and includes data on consumption, production, imports, exports, as well as market forecasts.
The other chapters are in-depth per-country market studies.
Country coverage
Egypt, the largest pharmaceutical market of the region
Israel, home to the world's largest generic drug company
Jordan, the leading Arab pharmaceutical exporter
Lebanon, an almost exclusive import market
Saudi Arabia, the largest market of the Gulf
The United Arab Emirates, among the highest-priced markets in the region
Five key findings
Overall the Middle East’s pharmaceutical market is valued at more than $12bn and is expected to grow at healthy 10-15% annually.
There are more than 450 pharmaceutical manufacturers in the Middle East - With the exception of Egypt, all Middle Eastern countries are high importers of branded drugs. Egypt is over 90% self-sufficient in its medicine needs
Saudi Arabia, as the richest regional market, has embarked on an ambitious hospital building project - Major growth drivers are greater access to generics and innovative new medicines as primary care improves and more people are covered by health insurance.
Countries are increasingly adopting liberal economic policies in the healthcare sector
Local manufacturing capabilities are constrained to generics.
A high acceptance of Western medicines is present
What you can learn from this repor
Which multinationals have invested in the Middle East
Who are the leading local pharmaceutical manufacturers and distributors
What are the trends in the pharmaceutical market and import and export sizes
How Intellectual Property Rights and patents are the most conflictual regional issue
Which countries have implemented health insurance and the likely impact on growth
What type of demand and supply-side cost controls are in place
(0 items)
